US5319098A - Process for the stereoselective preparation of L-alanyl-L-proline - Google Patents
Process for the stereoselective preparation of L-alanyl-L-proline Download PDFInfo
- Publication number
- US5319098A US5319098A US08/063,434 US6343493A US5319098A US 5319098 A US5319098 A US 5319098A US 6343493 A US6343493 A US 6343493A US 5319098 A US5319098 A US 5319098A
- Authority
- US
- United States
- Prior art keywords
- proline
- alanyl
- pyruvyl
- mmoles
- process according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010087924 alanylproline Proteins 0.000 title claims abstract description 29
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims description 11
- 230000000707 stereoselective effect Effects 0.000 title claims description 6
- ZITOPJKFJBLAMM-LURJTMIESA-N (2s)-1-(2-oxopropanoyl)pyrrolidine-2-carboxylic acid Chemical compound CC(=O)C(=O)N1CCC[C@H]1C(O)=O ZITOPJKFJBLAMM-LURJTMIESA-N 0.000 claims abstract description 21
- 239000003054 catalyst Substances 0.000 claims abstract description 9
- 238000007327 hydrogenolysis reaction Methods 0.000 claims abstract description 7
- 229910052751 metal Inorganic materials 0.000 claims abstract description 6
- 239000002184 metal Substances 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 239000007868 Raney catalyst Substances 0.000 claims description 5
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 150000002466 imines Chemical class 0.000 claims description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 229910052702 rhenium Inorganic materials 0.000 claims description 2
- 229910052703 rhodium Inorganic materials 0.000 claims description 2
- 239000010948 rhodium Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical group [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims 1
- -1 2,2-disubstituted propionyl halide Chemical class 0.000 abstract description 18
- 229960002429 proline Drugs 0.000 abstract description 12
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract description 9
- 229930182821 L-proline Natural products 0.000 abstract description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- IPMNUMPMMAFDHR-YFKPBYRVSA-N (2s)-1-(2,2-dichloropropanoyl)pyrrolidine-2-carboxylic acid Chemical compound CC(Cl)(Cl)C(=O)N1CCC[C@H]1C(O)=O IPMNUMPMMAFDHR-YFKPBYRVSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- NDUPDOJHUQKPAG-UHFFFAOYSA-M 2,2-Dichloropropanoate Chemical compound CC(Cl)(Cl)C([O-])=O NDUPDOJHUQKPAG-UHFFFAOYSA-M 0.000 description 2
- IPKCHUGFUGHNRZ-UHFFFAOYSA-N 2,2-dichloropropanoyl chloride Chemical compound CC(Cl)(Cl)C(Cl)=O IPKCHUGFUGHNRZ-UHFFFAOYSA-N 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 125000000746 allylic group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NVSYANRBXPURRQ-UHFFFAOYSA-N naphthalen-1-ylmethanamine Chemical compound C1=CC=C2C(CN)=CC=CC2=C1 NVSYANRBXPURRQ-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 235000013930 proline Nutrition 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- RTCUCQWIICFPOD-VIFPVBQESA-N (1s)-1-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C([C@@H](N)C)=CC=CC2=C1 RTCUCQWIICFPOD-VIFPVBQESA-N 0.000 description 1
- MDZXHLVJLVSLSB-YFKPBYRVSA-N (2s)-1-(3,3-dichloropropanoyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CC(Cl)Cl MDZXHLVJLVSLSB-YFKPBYRVSA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- PPKAIMDMNWBOKN-UHFFFAOYSA-N 2-Oxo-4-phenylbutyric acid Chemical compound OC(=O)C(=O)CCC1=CC=CC=C1 PPKAIMDMNWBOKN-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- HCFKSOKVOFMSEP-UHFFFAOYSA-N 3,3-dichloropropanoyl chloride Chemical compound ClC(Cl)CC(Cl)=O HCFKSOKVOFMSEP-UHFFFAOYSA-N 0.000 description 1
- DTETYCNJKAUROO-UHFFFAOYSA-N 4-methyl-1,3-oxazolidine-2,5-dione Chemical compound CC1NC(=O)OC1=O DTETYCNJKAUROO-UHFFFAOYSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- QLRRUWXMMVXORS-UHFFFAOYSA-N Augustine Natural products C12=CC=3OCOC=3C=C2CN2C3CC(OC)C4OC4C31CC2 QLRRUWXMMVXORS-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- NDUPDOJHUQKPAG-UHFFFAOYSA-N Dalapon Chemical compound CC(Cl)(Cl)C(O)=O NDUPDOJHUQKPAG-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 150000002917 oxazolidines Chemical class 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000011924 stereoselective hydrogenation Methods 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- This invention pertains to a process for the stereo-selective preparation of L-alanyl-L-proline.
- the dipeptide L-alanyl-L-proline is a known chemical intermediate useful in the preparation of various pharmaceutical agents having enzyme inhibiting properties.
- Angiotensin converting enzyme for example is a carboxyl terminal dipeptidyl exopeptidase [E.C. 3.4.15.1] which converts angiotensin I into angiotensin II, a potent vasoconstrictor.
- Numerous compounds have been described which reduce blood pressure in humans by inhibiting the renin-angiotensin system (generally referred to as angiotensin converting enzyme inhibitors or simply ACE inhibitors).
- ACE inhibitors have a dipeptide or tripeptide-type structure, typically but not invariable including an alanine component bound through its carboxy group to a nitrogen containing heterocyclic group in which a carboxy group is in the ⁇ -position to the nitrogen atom of the heterocyclic group.
- Two examples of such compounds are enalapril, which is N 2 -[(S)-1-ethoxycarbonyl-3-phenyl-propyl]-L-alanyl-L-proline, and enalaprilat, which is N 2 -[(S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline.
- L-alanyl-L-proline is coupled with an alkyl ester of 2-oxo-4-phenyl-butyrate; see Blacklock et al., J. Org. Chem. 3, 836-841 (1988).
- L-Alanyl-L-proline contains two chiral centers and a third chiral center is generated in this condensation.
- the condensation is reported to provide high diastereoselectivity, the ratio of the desired SSS diastereoisomer to the unwanted RSS diastereoisomer is reported to be 87:13.
- N-(t-butoxycarbonyl)-L-alanine can be coupled with the benzyl ester of L-proline in the presence of dicyclohexylcarbodiimide and the resulting benzyl ester of N-(t-butoxycarbonyl)-L-alanyl-L-proline treated with trifluoroacetic acid to remove the N-(t-butoxycarbonyl) group.
- Hydrolysis to cleave the benzyl ester then yields L-alanyl-L-proline. See Kleemann et al., Pharmazeutician Wirkstoffe, 1154 (1987).
- the present invention pertains to a new process for the stereoselective preparation of L-alanyl-L-proline from inexpensive starting materials.
- the process involves the hydrogenation, in the presence of a metal hydrogenolysis catalyst and at a pH of less than about 4, of an imine (including hydroxyimine) of the formula: ##STR1## where R is a hydrogenolytically labile group and R 1 is hydrogen or a hydrogenolytically removable carboxy protecting group.
- the hydrogenolytically removable carboxy protecting groups encompassed by R 1 typically are ester groups which are removable under sufficiently mild conditions of hydrogenation.
- This can be for example a lower alkyl ester of 1 to 12 carbon atoms such as methyl or ethyl or such an alkyl group which is (i) unsaturated such as vinyl or aryl, (ii) branched such as t-butyl, or (iii) substituted in the 1- or 2-position with lower alkoxy, such as for example, methoxymethyl, 1-methoxyethyl, and ethoxymethyl, lower alkylthio, such as for example methylthiomethyl and 1-ethylthioethyl; halogen, such as 2,2,2-trichloroethyl, 2-bromoethyl, and 2-iodoethoxycarbonyl; one or two phenyl groups each of which can be unsubstituted or mono-, di- or tri-substituted with,
- R 1 is such a hydrogenolytically removable carboxy protecting group
- the carboxy group in the pro-line portion of the molecule need not be protected; i.e., R 1 can be hydrogen, thereby reducing the number of synthetic steps by eliminating the need to remove such a protecting group.
- Such groups include cyano, allylic groups (including cyclic allylic groups such as cyclohex-2-en-1-yl), nitro, amino, alkoxy of 1 to 4 carbon atoms, hydroxy, carboxy, carbalkoxy, aryl such as phenyl and naphthyl, and aralkyl such as benzyl, phenethyl and similar groups as discussed above in greater detail in connection with R 1 .
- R preferably is hydroxy, alkyl, alkoxy, aralkyl, or aralkoxy and most preferably hydroxy.
- R preferably is hydroxy, alkyl, alkoxy, aralkyl, or aralkoxy and most preferably hydroxy.
- the metal hydrogenolysis catalyst include known materials and typically are metals of Group 8 such as nickel, palladium, rhenium, platinum, or rhodium. Preparations such as Raney nickel or palladium hydroxide can be employed and the catalyst can be supported on carrier such as carbon or alumina.
- the hydrogenation is carried out under strongly acidic conditions; i.e., at a pH of less than about 4.
- the reaction can be conducted in the presence or absence of an organic solvent.
- the solvent can be any inert organic liquid in which the reactant is soluble and which is substantially inert to hydrogenation, as for example lower alkanols, alkanoic acids, alkanes and the like.
- the compounds of Formula I are readily prepared through treatment of N-pyruvyl-L-proline with an amine of the formula H 2 N--R.
- the reaction can be conducted under conditions which remove water, as for example through use of a Dean-Stark apparatus or by addition of molecular sieves.
- Typical amines include aminodiphenyl-methane, naphth-1-ylmethylamine, benzylamine, hydroxylamine, S-(-)- ⁇ -phenethylamine, S-(-)-1-(1-naphthyl)ethylamine, and the like.
- the treatment of N-pyruvyl-L-proline with an amine to form a compound of Formula I and the stereo-selective hydrogenation to L-alanyl-L-proline can be conducted in the same reaction vessel, thereby minimizing equipment and potential transfer loss.
- the entire reaction sequence described herein, from L-proline and a 2-X-2-Y-propionyl halide to L-alanyl-L-proline can be conducted without the need to isolate or purify any of the intermediate products.
- N-Pyruvyl-L-proline is commercially available or can be prepared through any of the known techniques.
- the present invention also provides an improved process for the preparation of N-pyruvyl-L-proline (including carboxy protected N-pyruvyl-L-proline derivatives) in which a compound of the formula: ##STR2## where X and Y are chloro, bromo, iodo, or together alkylidenedioxy and R 1 is hydrogen or a hydrogenolytically removable carboxy protecting group, is hydrolyzed at a pH range of from about 6.5 to about 8.5, preferably at a pH of from about 7 to about 8.
- This pH range can be controlled through continued addition of base or acid as required or, more conveniently, through use of a buffer.
- a compound of Formula II can simply be heated in an aqueous media to afford the desired N-pyruvyl-L-proline.
- R 1 is hydrogen and X and Y are chloro.
- a compound of Formula II can be readily prepared by allowing L-proline and the corresponding 2-X-2-Y-propionyl halide to react in the presence of sufficient aqueous base to provide a pH of at least 9.
- the reaction is conducted in an inert organic solvent and ideally, there is sufficient aqueous base is present to provide a pH of at least 11.
- the present invention permits stereoselective preparation of L-alanyl-L-proline through a four-step process in which (i) L-proline and a 2-X-2-Y-propionyl halide are allowed to react at a pH of at least 9 to produce an N-(2-X-2-Y-propionyl)-L-proline, (ii) this L-proline compound is hydrolyzed at a pH range of from about 6.5 to about 8.5 to yield N-pyruvyl-L-proline, (iii) N-pyruvyl-L-proline is treated with an amine to yield a compound of Formula I, and (iv) the latter is hydrogenated to yield L-alanyl-L-proline in high stereospecificity.
- the ratio of L-alanyl-L-proline to D-alanyl-L-proline was determined by HPLC using a Waters 510 HPLC pump, Waters 712 WISP, Waters RCM 8 ⁇ 10 Novopak column, Waters 486 Tunable Absorbance Detector, and Shimadzu CR601 Chromatopac Recorder.
- a mixture of 19 parts of 0.15% aqueous phosphoric acid containing 10 mM octanesulfonic to one part isopropanol can be used as eluant.
- the flow rate was 1.5 mL/minute with detection at 210 nm.
- L-alanyl-L-proline The retention time of L-alanyl-L-proline is 22 minutes, that of D-alanyl-L-proline is 26 minutes.
- Gas chromatography employed a Supelco SPB-1 Column running at 75° C. for 10 minutes, then 20° C. per minute, then 170° C. for 5 minutes.
- N-pyruvyl-L-proline (0.085 g., 0.46 mmoles, 1.0 eq.), naphth-1-ylmethylamine (0.144 g., 0.92 mmoles, 2.0 eq.), and 2.0 mL absolute ethanol.
- the reaction mixture and 100 mL of ethanol were transferred under nitrogen to a 500 mL Parr shaker flask previously flushed with nitrogen.
- Palladium-on-carbon (0.02 g., 0.18 mmoles, 0.4 eq.) was added together with 50 mL absolute ethanol.
- N-pyruvyl-L-proline utilized as starting material can be conveniently obtained from 2,2-dichloropropionic acid according to the following procedure.
- reaction mixture were transferred to a 1 L flask with an additional 200 mL of water as a rinse.
- the methylene chloride was removed by evaporation and the pH adjusted to 2.
- the solid which forms was collected by filtration using cold water as a rinse to yield N-(2,2-dichloropropionyl)proline which was dried under vacuum (0.1 Torr) for 15 hours to give 44.3 g. (78% yield) which can be further purified through recrystallization from ethyl acetate or ethyl acetate:hexane. m.p. 61°-62° C.
- N-pyruvyl-L-proline (0.085 g., 0.46 mmoles, 1.0 eq.), benzylamine (0.098 g., 0.9 mmoles, 2.0 eq.), and 2.0 mL absolute ethanol.
- the reaction mixture and 100 mL of ethanol were transferred under nitrogen to a 500 mL of ethanol were transferred under nitrogen to a 500 mL Parr shaker flask previously been flushed with nitrogen.
- N-pyruvyl-L-proline (0.085 g., 0.46 mmoles, 1.0 eq.), hydroxylamine hydrochloride (0.048 g., 0.69 mmoles, 1.5 eq.), sodium acetate (0.056 g., 0.69 mmoles, 1.5 eq.), and 2 mL water and 10 mL ethanol were added to a 25 mL flask. The suspension was heated to reflux for 2 h. The imine was transferred under nitrogen gas with 100 mL ethanol to a 250 mL Parr flask.
- N-pyruvyl-L-proline 0.085 g., 0.46 mmoles, 1.0 eq.
- S-(-)- ⁇ -phenethylamine 0.110 g., 0.91 mmoles, 2.0 eq.
- 0.5 mL absolute ethanol 0.5 mL absolute ethanol.
- Raney nickel (0.01 g., 0.17 mmoles, 0.4 eq.) in water was washed with absolute ethanol three times on a Buchner funnel under vacuum and added to the Parr flask with 50 mL absolute ethanol. Nitrogen was bubbled through the suspension for 5 minutes and acetic acid (0.5 mL), 8.7 mmoles, 19 eq.) was added. Nitrogen was bubbled for an additional 2 minutes. The material was hydrogenated at 50 psi (with three alternating vacuum/hydrogen gas cycles) for 16.5 hours and then filtered through Celite into a fresh 500 mL Parr flask, washing with 200 mL absolute ethanol.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
______________________________________ Hydrogenolysis Diastereomeric Catalysts Excess ______________________________________ Raney nickel/acetic acid 32% rhenium-on-carbon >99.5% palladium-on-carbon >99.5% platinum-on-carbon >99.5% rhodium-on-carbon >99.5% rhodium-on-alumina 47% ______________________________________
Claims (7)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/063,434 US5319098A (en) | 1993-05-18 | 1993-05-18 | Process for the stereoselective preparation of L-alanyl-L-proline |
PCT/US1994/005553 WO1994026771A1 (en) | 1993-05-18 | 1994-05-18 | Process for the stereoselective preparation of l-alanyl-l-proline |
US08/249,326 US5424454A (en) | 1993-05-18 | 1994-05-26 | Process for the stereoselective preparation of l-alanyl-l-proline |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/063,434 US5319098A (en) | 1993-05-18 | 1993-05-18 | Process for the stereoselective preparation of L-alanyl-L-proline |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/249,326 Continuation-In-Part US5424454A (en) | 1993-05-18 | 1994-05-26 | Process for the stereoselective preparation of l-alanyl-l-proline |
Publications (1)
Publication Number | Publication Date |
---|---|
US5319098A true US5319098A (en) | 1994-06-07 |
Family
ID=22049164
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/063,434 Expired - Lifetime US5319098A (en) | 1993-05-18 | 1993-05-18 | Process for the stereoselective preparation of L-alanyl-L-proline |
US08/249,326 Expired - Lifetime US5424454A (en) | 1993-05-18 | 1994-05-26 | Process for the stereoselective preparation of l-alanyl-l-proline |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/249,326 Expired - Lifetime US5424454A (en) | 1993-05-18 | 1994-05-26 | Process for the stereoselective preparation of l-alanyl-l-proline |
Country Status (2)
Country | Link |
---|---|
US (2) | US5319098A (en) |
WO (1) | WO1994026771A1 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424454A (en) * | 1993-05-18 | 1995-06-13 | Celgene Corporation | Process for the stereoselective preparation of l-alanyl-l-proline |
US5795908A (en) * | 1995-06-07 | 1998-08-18 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
US5801197A (en) * | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
US5801187A (en) * | 1996-09-25 | 1998-09-01 | Gpi-Nil Holdings, Inc. | Heterocyclic esters and amides |
US5990131A (en) * | 1996-09-25 | 1999-11-23 | Gpi Nil Holdings Inc. | Heterocyclic thioesters and ketones |
US6004993A (en) * | 1997-06-04 | 1999-12-21 | Gpi Nil Holdings, Inc. | N-linked sulfonamide of heterocyclic thioester hair growth compounds and uses |
US6025500A (en) * | 1998-09-23 | 2000-02-15 | Merck & Co., Ltd. | Stereoselective process for enalapril |
US6172087B1 (en) | 1998-06-03 | 2001-01-09 | Gpi Nil Holding, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
US6187796B1 (en) | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Sulfone hair growth compositions and uses |
US6187784B1 (en) | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Pipecolic acid derivative hair growth compositions and uses |
US6218423B1 (en) | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
US6218424B1 (en) | 1996-09-25 | 2001-04-17 | Gpi Nil Holdings, Inc. | Heterocyclic ketone and thioester compounds and uses |
US6271244B1 (en) | 1998-06-03 | 2001-08-07 | Gpi Nil Holdings, Inc. | N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses |
US6274602B1 (en) | 1998-06-03 | 2001-08-14 | Gpi Nil Holdings, Inc. | Heterocyclic thioester and ketone hair growth compositions and uses |
US6274617B1 (en) | 1998-06-03 | 2001-08-14 | Gpi Nil Holdings, Inc. | Heterocyclic ester and amide hair growth compositions and uses |
US6333340B1 (en) | 1998-08-14 | 2001-12-25 | Gpi Nil Holdings, Inc. | Small molecule sulfonamides for vision and memory disorders |
US6335348B1 (en) | 1998-08-14 | 2002-01-01 | Gpi Nil Holdings, Inc. | Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders |
US6337340B1 (en) | 1998-08-14 | 2002-01-08 | Gpi Nil Holdings, Inc. | Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders |
US6339101B1 (en) | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
US6376517B1 (en) | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
US6384056B1 (en) | 1998-08-14 | 2002-05-07 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters or ketones for vision and memory disorders |
US6395758B1 (en) | 1998-08-14 | 2002-05-28 | Gpi Nil Holdings, Inc. | Small molecule carbamates or ureas for vision and memory disorders |
US6399648B1 (en) | 1998-08-14 | 2002-06-04 | Gpi Nil Holdings, Inc. | N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders |
US6429215B1 (en) | 1998-06-03 | 2002-08-06 | Gpi Nil Holdings, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
US6462072B1 (en) | 1998-09-21 | 2002-10-08 | Gpi Nil Holdings, Inc. | Cyclic ester or amide derivatives |
US20020198250A1 (en) * | 1997-06-04 | 2002-12-26 | Steiner Joseph P. | Pyrrolidine derivative hair growth compositions and uses |
US6506788B1 (en) | 1998-08-14 | 2003-01-14 | Gpi Nil Holdings, Inc. | N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders |
US20050106703A1 (en) * | 2003-11-05 | 2005-05-19 | Kyowa Hakko Kogyo Co., Ltd. | Microorganisms producing dipeptides and process for producing dipeptides using the microorganisms |
US7153883B2 (en) * | 1998-06-03 | 2006-12-26 | Gpi Nil Holdings Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
US7338976B1 (en) | 1998-08-14 | 2008-03-04 | Gpi Nil Holdings, Inc. | Heterocyclic esters or amides for vision and memory disorders |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5846979A (en) * | 1997-02-28 | 1998-12-08 | Gpi Nil Holdings, Inc. | N-oxides of heterocyclic esters, amides, thioesters, and ketones |
CZ291417B6 (en) * | 1997-08-06 | 2003-03-12 | Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg | Process for preparing N-pyruvyl-L-proline |
AT405400B (en) * | 1997-11-12 | 1999-07-26 | Chemie Linz Gmbh | Process for the preparation of 1-pyruvoyl-L-proline |
AT405399B (en) * | 1997-08-06 | 1999-07-26 | Chemie Linz Gmbh | Process for the preparation of 1-pyruvoyl-L-proline |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868312A (en) * | 1987-05-29 | 1989-09-19 | Hamari Chemicals Ltd. | N.sup.ε -trifluoroacetyl-L-lysyl-L-proline.D-10-camphorsulfonic acid salt and process for producing the same |
US4943640A (en) * | 1983-10-14 | 1990-07-24 | The Dow Chemical Company | Preparation of 5-(1-alkyl-carbonyloxy)alkylpyrrolidin-2-one |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0662671B2 (en) * | 1986-01-17 | 1994-08-17 | 株式会社大塚製薬工場 | Proline derivative |
DE4123248C2 (en) * | 1991-07-13 | 1996-03-07 | Degussa | Process for the preparation of N-substituted alpha-amino acids and alpha-amino acid derivatives |
US5319098A (en) * | 1993-05-18 | 1994-06-07 | Celgene Corporation | Process for the stereoselective preparation of L-alanyl-L-proline |
-
1993
- 1993-05-18 US US08/063,434 patent/US5319098A/en not_active Expired - Lifetime
-
1994
- 1994-05-18 WO PCT/US1994/005553 patent/WO1994026771A1/en active Application Filing
- 1994-05-26 US US08/249,326 patent/US5424454A/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4943640A (en) * | 1983-10-14 | 1990-07-24 | The Dow Chemical Company | Preparation of 5-(1-alkyl-carbonyloxy)alkylpyrrolidin-2-one |
US4868312A (en) * | 1987-05-29 | 1989-09-19 | Hamari Chemicals Ltd. | N.sup.ε -trifluoroacetyl-L-lysyl-L-proline.D-10-camphorsulfonic acid salt and process for producing the same |
Non-Patent Citations (2)
Title |
---|
Blacklock, et al., J. Org. Chem., 53(1988), pp. 836 841. * |
Blacklock, et al., J. Org. Chem., 53(1988), pp. 836-841. |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424454A (en) * | 1993-05-18 | 1995-06-13 | Celgene Corporation | Process for the stereoselective preparation of l-alanyl-l-proline |
US6140357A (en) * | 1995-06-07 | 2000-10-31 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
US20100145071A1 (en) * | 1995-06-07 | 2010-06-10 | Gliamed, Inc. | Small molecule inhibitors of rotamase enzyme activity |
US7652060B2 (en) | 1995-06-07 | 2010-01-26 | Glia Med, Inc | Small molecule rotamase enzyme inhibitors |
US5859031A (en) * | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
US7282510B2 (en) | 1995-06-07 | 2007-10-16 | Gliamed, Inc. | Small molecule inhibitors of rotamase enzyme activity |
US7960570B2 (en) | 1995-06-07 | 2011-06-14 | Gliamed, Inc. | Small molecule inhibitors of rotamase enzyme activity |
US20110218343A1 (en) * | 1995-06-07 | 2011-09-08 | Gliamed, Inc. | Small molecule inhibitors of rotamase enzyme activity |
US20080076817A1 (en) * | 1995-06-07 | 2008-03-27 | Hamilton Gregory S | Small Molecule Rotamase Enzyme Inhibitors |
US5795908A (en) * | 1995-06-07 | 1998-08-18 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
US5801197A (en) * | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
US6417209B2 (en) | 1996-09-25 | 2002-07-09 | Gpi Nil Holdings, Inc. | Heterocyclic ketone and thioester compounds and uses |
US20050148637A1 (en) * | 1996-09-25 | 2005-07-07 | Gpi Nil Holdings, Inc. | Heterocyclic ketone and thioester compounds and uses |
US20040106652A1 (en) * | 1996-09-25 | 2004-06-03 | Gpi Nil Holdings, Inc. | Heterocyclic ketone and thioester compounds and uses |
US6984639B2 (en) | 1996-09-25 | 2006-01-10 | Gpi Nil Holdings, Inc. | Heterocyclic ketone and thioester compounds and uses |
US5990131A (en) * | 1996-09-25 | 1999-11-23 | Gpi Nil Holdings Inc. | Heterocyclic thioesters and ketones |
US6200972B1 (en) | 1996-09-25 | 2001-03-13 | Gpi Nil Holdings, Inc. | Heterocyclic esters and amides |
US5801187A (en) * | 1996-09-25 | 1998-09-01 | Gpi-Nil Holdings, Inc. | Heterocyclic esters and amides |
US6218424B1 (en) | 1996-09-25 | 2001-04-17 | Gpi Nil Holdings, Inc. | Heterocyclic ketone and thioester compounds and uses |
US6004993A (en) * | 1997-06-04 | 1999-12-21 | Gpi Nil Holdings, Inc. | N-linked sulfonamide of heterocyclic thioester hair growth compounds and uses |
US6194440B1 (en) | 1997-06-04 | 2001-02-27 | Gpi Nil Holdings, Inc. | Small molecule carbamate or urea hair growth compositions and uses |
US6191125B1 (en) | 1997-06-04 | 2001-02-20 | Gpi Nil Holdings, Inc. | Small molecule pipecolic acid derivative hair growth compositions and uses |
US6943187B2 (en) | 1997-06-04 | 2005-09-13 | Gpi Nil Holdings, Inc. | Pyrrolidine derivative hair growth compositions and uses |
US6187806B1 (en) | 1997-06-04 | 2001-02-13 | Gpi Nil Holdings | N-linked sulfone of heterocyclic thioester hair growth compositions and uses |
US20050059693A1 (en) * | 1997-06-04 | 2005-03-17 | Gpi Nil Holdings, Inc. | Heterocyclic thioester and ketone hair growth compositions and uses |
US6177455B1 (en) | 1997-06-04 | 2001-01-23 | Gpi Nil Holdings, Inc. | Pyrrolidine derivative hair growth compositions and uses |
US20020198250A1 (en) * | 1997-06-04 | 2002-12-26 | Steiner Joseph P. | Pyrrolidine derivative hair growth compositions and uses |
US6187796B1 (en) | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Sulfone hair growth compositions and uses |
US20010041733A1 (en) * | 1998-06-03 | 2001-11-15 | Gpi Nil Holdings, Inc. | Heterocyclic ester and amide hair growth compositions and uses |
US6271244B1 (en) | 1998-06-03 | 2001-08-07 | Gpi Nil Holdings, Inc. | N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses |
US6274602B1 (en) | 1998-06-03 | 2001-08-14 | Gpi Nil Holdings, Inc. | Heterocyclic thioester and ketone hair growth compositions and uses |
US7153883B2 (en) * | 1998-06-03 | 2006-12-26 | Gpi Nil Holdings Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
US6429215B1 (en) | 1998-06-03 | 2002-08-06 | Gpi Nil Holdings, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
US6274617B1 (en) | 1998-06-03 | 2001-08-14 | Gpi Nil Holdings, Inc. | Heterocyclic ester and amide hair growth compositions and uses |
US6187784B1 (en) | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Pipecolic acid derivative hair growth compositions and uses |
US6172087B1 (en) | 1998-06-03 | 2001-01-09 | Gpi Nil Holding, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
US6337340B1 (en) | 1998-08-14 | 2002-01-08 | Gpi Nil Holdings, Inc. | Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders |
US6335348B1 (en) | 1998-08-14 | 2002-01-01 | Gpi Nil Holdings, Inc. | Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders |
US6506788B1 (en) | 1998-08-14 | 2003-01-14 | Gpi Nil Holdings, Inc. | N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders |
US6333340B1 (en) | 1998-08-14 | 2001-12-25 | Gpi Nil Holdings, Inc. | Small molecule sulfonamides for vision and memory disorders |
US6339101B1 (en) | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
US6384056B1 (en) | 1998-08-14 | 2002-05-07 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters or ketones for vision and memory disorders |
US6376517B1 (en) | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
US6399648B1 (en) | 1998-08-14 | 2002-06-04 | Gpi Nil Holdings, Inc. | N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders |
US7338976B1 (en) | 1998-08-14 | 2008-03-04 | Gpi Nil Holdings, Inc. | Heterocyclic esters or amides for vision and memory disorders |
US6395758B1 (en) | 1998-08-14 | 2002-05-28 | Gpi Nil Holdings, Inc. | Small molecule carbamates or ureas for vision and memory disorders |
US6218423B1 (en) | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
US6462072B1 (en) | 1998-09-21 | 2002-10-08 | Gpi Nil Holdings, Inc. | Cyclic ester or amide derivatives |
US6025500A (en) * | 1998-09-23 | 2000-02-15 | Merck & Co., Ltd. | Stereoselective process for enalapril |
US20100120126A1 (en) * | 2003-11-05 | 2010-05-13 | Kyowa Hakko Bio Co., Ltd. | Microorganisms producing dipeptides and process for producing dipeptide using the microorganisms |
US20050106703A1 (en) * | 2003-11-05 | 2005-05-19 | Kyowa Hakko Kogyo Co., Ltd. | Microorganisms producing dipeptides and process for producing dipeptides using the microorganisms |
Also Published As
Publication number | Publication date |
---|---|
US5424454A (en) | 1995-06-13 |
WO1994026771A1 (en) | 1994-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5319098A (en) | Process for the stereoselective preparation of L-alanyl-L-proline | |
CA1244041A (en) | Process for the preparation of cis, endo- octahydrocyclopenta¬b|pyrrole-2-carboxylate | |
Krol et al. | Stereochemical correlation of proclavaminic acid and syntheses of erythro-and threo-L-. beta.-hydroxyornithine from an improved vinylglycine synthon | |
Chung et al. | Conformationally constrained amino acids. Synthesis and optical resolution of 3-substituted proline derivatives | |
Freidinger | Synthesis of. gamma.-lactam-constrained tryptophyl-lysine derivatives | |
JPS6233141A (en) | Intermediate for polypeptide synthesis | |
EP0889874B1 (en) | 7-amino-2-heptenoates and their use in the preparation of methylphenidate | |
Kammermeier et al. | Vanadium (II)‐and Niobium (III)‐Induced, Diastereoselective Pinacol Coupling of Peptide Aldehydes to Give a C2‐Symmetrical HIV Protease Inhibitor | |
OTSUKA et al. | Synthetic studies on an antitumor antibiotic, Bleomycin. XII. Preparation of an l-2, 3-diaminopropionic acid derivative as a synthetic intermediate | |
MXPA98007879A (en) | 7-amino-2-heptenoatos and its use in the preparation of metilfenid | |
JP2002507624A5 (en) | ||
AU2003224420B2 (en) | Process for preparation of perindopril and salts thereof | |
CA1240700A (en) | PROCESS FOR PREPARATION OF .alpha.-ALKYL AMINO ACIDS | |
US6034247A (en) | Oxazolidinones and methods for the synthesis and use of same | |
WO1996004277A1 (en) | Pyrrolinone-based peptidomimetics | |
CA1322075C (en) | Flourine containing renin inhibitors | |
CA1277993C (en) | N2-(1-carboxy-3-oxo-3-phenylpropyl)-l-lysine compounds and their derivatives | |
US5489692A (en) | Pyrrolinone-based compounds | |
BG64050B1 (en) | Method for preparing aminoderivatives of alkyloxy furanone derivatives, compounds obtained by said method and use of said compounds | |
US6130331A (en) | Chemical synthesis of a chiral 1,4-oxazin-2-one | |
KUBOTA et al. | Studies on Angiotensin Converting Enzyme Inhibitors. V. The Diastereoselective Syntheis of 2-Oxomidazolidine Derivatives | |
US5959141A (en) | 1-amino-2-hydroxycycloalkanecarboxylic acid derivatives | |
US4442030A (en) | Process for preparing carboxyalkyl dipeptides | |
Achatz et al. | Asymmetric Synthesis Employing a Chiral 5‐Methoxy‐1, 4‐oxazin‐2‐one Derivative: Preparation of Enantiomerically Pure α‐Quaternary α‐Amino Acids | |
WO1998035934A1 (en) | η-OXO-HOMOPHENYLALANINE DERIVATIVES AND PROCESS FOR PRODUCING HOMOPHENYLALANINE DERIVATIVES BY REDUCING THE SAME |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING |
|
AS | Assignment |
Owner name: CELGENE CORPORATION, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BURBAUM, BEVERLY W.;LI, CHUNSHI;MATCHAM, GEORGE W.;REEL/FRAME:006604/0468 Effective date: 19930519 |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS - SMALL BUSINESS (ORIGINAL EVENT CODE: SM02); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 12 |